-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on ADC Therapeutics, Lowers Price Target to $5

Benzinga·06/20/2025 13:55:48
Listen to the news
RBC Capital analyst Leonid Timashev maintains ADC Therapeutics (NYSE:ADCT) with a Outperform and lowers the price target from $8 to $5.